** Medical device maker Solventum's SOLV.N shares rise ~2.6% to $77.82
** Argus Research upgrades Solventum to "buy" from "hold"
** Brokerage says SOLV transformed into faster-growing and higher-margin business model
** Argus raises SOLV's 2026 adjusted EPS estimate to $5.98 from $5.95
** Four of 13 brokerages rate stock "buy" or higher, eight "hold" and one "sell"; their median PT is $85 - LSEG data
** Including session's moves, stock up ~17.3% YTD
(Reporting by Prakhar Srivastava in Bengaluru)
((Prakhar.srivastava2@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。